All In Biotech

Drug Trial Radar · NCT05897424

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

A Phase 2, Single Arm, Open Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

185

Planned (sponsor's estimate)

Start

Jun 20, 2024

Primary completion

Jun 30, 2028

Study completion Sep 30, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema

Conditions

  • Alpha 1-Antitrypsin Deficiency
  • Emphysema

Interventions

  • SAR447537Drug

    A1PI, Recombinant, Bivalent Fc Fusion Protein

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long-term safety and tolerabilityTime frame: 3 years

Locations

40 sites in 9 countries. Site status is shown where the registry gives one.

  • UAB Lung Health Center- Site Number : 105

    Birmingham, Alabama

  • St Joseph's Hospital and Medical Center- Site Number : 126

    Phoenix, Arizona

  • David Geffen School of Medicine at UCLA- Site Number : 124

    Los Angeles, California

  • University of California Davis Medical Center- Site Number : 110

    Sacramento, California

  • National Jewish Medical and Research Center- Site Number : 123

    Denver, Colorado

  • Nuvance Health Medical Practices, Pulmonary & Sleep Specialists- Site Number : 119

    Danbury, Connecticut

  • University of Florida - Gainesville - 1600 SW Archer Rd- Site Number : 101

    Gainesville, Florida

  • Indiana University- Site Number : 127

    Indianapolis, Indiana

  • Brigham and Women's Hospital -75 Francis Street- Site Number : 131

    Boston, Massachusetts

  • University of Minnesota-420 Delaware Str SE- Site Number : 125

    Minneapolis, Minnesota

  • Hannibal Regional Healthcare System-HRMG-Hannibal- Site Number : 111

    Hannibal, Missouri

  • Columbia University Irving Medical Center- Site Number : 104

    New York, New York

  • Oregon Health and Science University- Site Number : 117

    Portland, Oregon

  • Penn State Health Milton S. Hershey Medical Center- Site Number : 122

    Hershey, Pennsylvania

  • Temple University Hospital - 3401 N Broad St- Site Number : 130

    Philadelphia, Pennsylvania

  • Velocity Clinical Research - Spartanburg - PPDS- Site Number : 120

    Spartanburg, South Carolina

  • Houston Methodist Hospital- Site Number : 113

    Houston, Texas

  • University of Utah Health Care- Site Number : 106

    Salt Lake City, Utah

  • Investigational Site Number : 202

    Chermside, Queensland, Australia

  • Investigational Site Number : 204

    South Brisbane, Queensland, Australia

  • Investigational Site Number : 201

    North Adelaide, South Australia, Australia

  • Investigational Site Number : 207

    Box Hill, Victoria, Australia

  • Investigational Site Number : 203

    Fitzroy, Victoria, Australia

  • Investigational Site Number : 205

    Frankston, Victoria, Australia

  • Investigational Site Number : 701

    Hellerup, Denmark

  • Investigational Site Number : 702

    Vejle, Denmark

  • Investigational Site Number : 501

    Dublin, Dublin, Ireland

  • Investigational Site Number : 403

    Auckland, New Zealand

  • Investigational Site Number : 404

    Wellington, New Zealand

  • Investigational Site Number : 802

    Krakow, Poland

  • Investigational Site Number : 801

    Warsaw, Masovian Voivodeship, Poland

  • Investigational Site Number : 902

    Madrid, Spain

  • Investigational Site Number : 903

    Santiago de Compostela, Spain

  • Investigational Site Number : 901

    Santander, Cantabria, Spain

  • Investigational Site Number : 601

    Gothenburg, Sweden

  • Investigational Site Number : 309

    Coventry, United Kingdom

  • Investigational Site Number : 308

    Dundee, Angus, United Kingdom

  • Investigational Site Number : 306

    Wythenshawe, Cheshire, United Kingdom

  • Investigational Site Number : 307

    Exeter, Devon, United Kingdom

  • Investigational Site Number : 304

    Southampton, Hampshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.